☆ 4.7 Article

A first-in-human trial on the safety and immunogenicity of COVID-eVax, a cellular response-skewed DNA vaccine against COVID-19

MOLECULAR THERAPY (2023)

Related references

Note: Only part of the references are listed.

Article Biochemistry & Molecular Biology

Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant

Yu Gao et al.

Summary: This study found that SARS-CoV-2 spike-specific CD4(+) and CD8(+) T cells induced by prior infection or BNT162b2 vaccination provide extensive immune coverage against the Omicron variant. Additionally, T cells induced by BNT162b2 vaccination exhibit higher cross-reactivity to the Omicron variant compared to T cells induced by prior SARS-CoV-2 infection.

NATURE MEDICINE (2022)

Add to Collection

Article Medicine, General & Internal

Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection

Victoria Hall et al.

Summary: This study investigated the duration and effectiveness of immunity among healthcare workers in the United Kingdom. It found that two doses of the BNT162b2 vaccine provided high short-term protection against SARS-CoV-2 infection, but this protection significantly decreased after six months. However, infection-acquired immunity boosted by vaccination remained high, even more than one year after infection.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Pharmacology & Pharmacy

Hypothesis: Possible influence of antivector immunity and SARS-CoV-2 variants on efficacy of ChAdOx1 nCoV-19 vaccine

Loris Zamai et al.

Summary: This study argues for the influence of anti-vector immunity and SARS-CoV-2 variants on the effectiveness of the ChAdOx1 nCoV-19 vaccine, emphasizing the importance of vaccinated individuals continuing to maintain preventive measures to prevent becoming potential spreaders. Mass vaccination is not seen as a quick solution to the pandemic, and discussions include potential consequences of SARS-CoV-2 evolution and repeated vaccinations, suggesting the adoption of an influenza-like vaccination strategy.

BRITISH JOURNAL OF PHARMACOLOGY (2022)

Add to Collection

Article Biotechnology & Applied Microbiology

COVID-eVax, an electroporated DNA vaccine candidate encoding the SARS-CoV-2 RBD, elicits protective responses in animal models

Antonella Conforti et al.

Summary: This study reports the preclinical evaluation of a novel COVID-19 vaccine candidate based on the electroporation of engineered, synthetic cDNA encoding a viral antigen in the skeletal muscle. The vaccine showed strong immunogenicity and significant protection in animal models, suggesting its potential as an ideal COVID-19 vaccine candidate for clinical development.

MOLECULAR THERAPY (2022)

Add to Collection

Article Multidisciplinary Sciences

T cell responses to SARS-CoV-2 spike cross-recognize Omicron

Roanne Keeton et al.

Summary: Despite reduced neutralizing antibody activity, T cell responses induced by vaccination or infection can cross-recognize the Omicron variant and provide protection.

NATURE (2022)

Add to Collection

Article Multidisciplinary Sciences

Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost

Frauke Muecksch et al.

Summary: Receiving three doses of an mRNA vaccine can provide protection against the Omicron variant and induce the production of more potent and broader antibodies. This is due to the expansion and evolution of memory B cell clones, particularly the newly emerging clones that target more conserved regions.

NATURE (2022)

Add to Collection

Review Multidisciplinary Sciences

Does a humoral correlate of protection exist for SARS-CoV-2? A systematic review

Julie Perry et al.

Summary: This article reviews the evidence for a humoral correlate of protection (CoP) for SARS-CoV-2. The findings suggest that higher antibody levels can decrease the risk of infection but do not eliminate it completely. The CoP for different variants is yet to be determined and further research is urgently needed.

PLOS ONE (2022)

Add to Collection

Article Immunology

Non-neutralizing antibodies: Deleterious or propitious during SARS-CoV-2 infection?

Isabella Zanella et al.

Summary: Antibody-dependent enhancement (ADE) is a complex phenomenon mediated by antibodies, but current data do not support its role in COVID-19 disease severity.

INTERNATIONAL IMMUNOPHARMACOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Safety and Immunogenicity of an Anti-Zika Virus DNA Vaccine

Pablo Tebas et al.

Summary: The study presented encouraging data on a DNA vaccine against Zika virus infection in a phase 1 clinical trial. The vaccine elicited anti-ZIKV immune responses with no serious adverse events reported at the interim analysis. Further studies are needed to evaluate the safety and efficacy of the vaccine.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

Correlates of protection against SARS-CoV-2 in rhesus macaques

Katherine McMahan et al.

Summary: Adoptive transfer of purified IgG from convalescent macaques protects naive macaques against SARS-CoV-2 infection, and cellular immune responses contribute to protection against rechallenge with SARS-CoV-2. The findings suggest that relatively low antibody titres are sufficient for protection against SARS-CoV-2 in macaques, while higher antibody titres are required for treatment of SARS-CoV-2 infection.

NATURE (2021)

Add to Collection

Article Medicine, General & Internal

Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine

J. Sadoff et al.

Summary: The study conducted a multicenter, placebo-controlled, phase 1-2a trial, with participants randomly assigned to receive the Ad26.COV2.S vaccine. The results showed that the safety and immunogenicity profiles of the vaccine support further development.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Immunology

BNT162b2 vaccination induces durable SARS-CoV-2-specific T cells with a stem cell memory phenotype

Gisella Guerrera et al.

Summary: Vaccination with the Pfizer-BioNTech mRNA vaccine induces a sustained anti-viral T cell response for at least 6 months, demonstrating immunological competence and long-term memory against SARS-CoV-2.

SCIENCE IMMUNOLOGY (2021)

Add to Collection

Editorial Material Medicine, General & Internal

From Vaccine Nationalism to Vaccine Equity - Finding a Path Forward

Ingrid T. Katz et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Review Immunology

Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2

Ian McDonald et al.

Summary: This study provides a comparative evaluation of different vaccine platforms in terms of immunogenicity and efficacy. Vaccines generally result in mild and self-limiting adverse events. Different vaccines show varying levels of immunogenicity and efficacy.

NPJ VACCINES (2021)

Add to Collection

Article Biochemistry & Molecular Biology

CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer

Erin M. Bange et al.

Summary: In patients with cancer and COVID-19, those with hematologic cancer show impaired immune responses compared to solid cancer patients. CD8 T cells play a crucial role in survival, even in the presence of limited humoral responses. The presence of SARS-CoV-2-specific T cell responses in hematologic cancer patients suggests a potential therapeutic target.

NATURE MEDICINE (2021)

Add to Collection

Article Pathology

Toxicity and Local Tolerance of COVID- eVax, a Plasmid DNA Vaccine for SARS-CoV-2, Delivered by Electroporation

Yuval Ramot et al.

Summary: COVID-19 is a rapidly spreading disease that poses a significant threat to global health, and the plasmid vaccine COVID-eVax has shown excellent safety and immune response in SD rats. The vaccine, administered intramuscularly followed by EP, is expected to induce muscle fiber necrosis and subchronic inflammation at the injection sites, which aids in mounting an immune response against the target antigen.

TOXICOLOGIC PATHOLOGY (2021)

Add to Collection

Article Immunology

Evidence for antibody as a protective correlate for COVID-19 vaccines

Kristen A. Earle et al.

Summary: The study found a strong correlation between antibody titers and efficacy when assessing different COVID-19 vaccines, supporting the use of post-immunization antibody titers as the basis for establishing a correlate of protection for COVID-19 vaccines.

VACCINE (2021)

Add to Collection

Article Medicine, General & Internal

Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in India

Taufik Momin et al.

Summary: The Phase 1 trial of ZyCoV-D DNA vaccine conducted in India showed that the vaccine is safe, well-tolerated, and immunogenic, warranting further investigation.

ECLINICALMEDICINE (2021)

Add to Collection

Article Medicine, Research & Experimental

SARS-CoV-2 mRNA vaccines induce broad CD4+ T cell responses that recognize SARS-CoV-2 variants and HCoV-NL63

Bezawit A. Woldemeskel et al.

Summary: Recent studies have shown that T cells can cross-recognize spike proteins of SARS-CoV-2 and common cold coronaviruses. Vaccination with SARS-CoV-2 mRNA vaccines results in broad T cell responses to the virus's spike protein, including potential recognition of variant spike proteins. Additionally, post-vaccination, there is an observed increase in CD4(+) T cell responses to certain common cold coronaviruses.

JOURNAL OF CLINICAL INVESTIGATION (2021)

Add to Collection

Review Immunology

Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection

Deborah Cromer et al.

Summary: The duration of immunity to COVID-19 and the risk of reinfection remain unclear. Immunity is crucial for long-term control of the pandemic, but studies suggest a decline in antibody responses and an increase in documented cases of reinfection with SARS-CoV-2. Understanding memory responses and immune control dynamics is essential for designing vaccines and predicting the future trajectory of the pandemic.

NATURE REVIEWS IMMUNOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial

Pablo Tebas et al.

Summary: The study found that the INO-4800 vaccine performed well in inducing immune responses and had good safety, with no serious adverse events reported. Participants exhibited both cellular and humoral immune responses to the vaccine, indicating its effectiveness in eliciting immunity.

ECLINICALMEDICINE (2021)

Add to Collection

Article Virology

Evaluation of SARS-CoV-2 neutralizing antibodies using a CPE-based colorimetric live virus micro-neutralization assay in human serum samples

Alessandro Manenti et al.

JOURNAL OF MEDICAL VIROLOGY (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology

Luca Piccoli et al.

CELL (2020)

Add to Collection

Article Multidisciplinary Sciences

A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity

Jingyun Yang et al.

NATURE (2020)

Add to Collection

Article Chemistry, Multidisciplinary

SARS-CoV-2 RBD Neutralizing Antibody Induction is Enhanced by Particulate Vaccination

Wei-Chiao Huang et al.

ADVANCED MATERIALS (2020)

Add to Collection

Review Biochemistry & Molecular Biology

A Critical Review of Electroporation as A Plasmid Delivery System in Mouse Skeletal Muscle

Emilia Sokolowska et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)

Add to Collection

Article Infectious Diseases

Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial

Kayvon Modjarrad et al.

LANCET INFECTIOUS DISEASES (2019)

Add to Collection

Review Immunology

A Comparison of Plasmid DNA and mRNA as Vaccine Technologies

Margaret A. Liu

VACCINES (2019)

Add to Collection

Review Pharmacology & Pharmacy

Clinical potential of electroporation for gene therapy and DNA vaccine delivery

Laure Lambricht et al.

EXPERT OPINION ON DRUG DELIVERY (2016)

Add to Collection

Article Immunology

Safety and Immunogenicity of DNA Vaccines Encoding Ebolavirus and Marburgvirus Wild-Type Glycoproteins in a Phase I Clinical Trial

Uzma N. Sarwar et al.

JOURNAL OF INFECTIOUS DISEASES (2015)

Add to Collection

Article Biotechnology & Applied Microbiology

Tolerability of intramuscular and intradermal delivery by CELLECTRA® adaptive constant current electroporation device in healthy volunteers

Malissa C. Diehl et al.

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2013)

Add to Collection

Review Immunology

Electroporation delivery of DNA vaccines: prospects for success

Niranjan Y. Sardesai et al.

CURRENT OPINION IN IMMUNOLOGY (2011)

Add to Collection

Article Immunology

A West Nile Virus DNA Vaccine Utilizing a Modified Promoter Induces Neutralizing Antibody in Younger and Older Healthy Adults in a Phase I Clinical Trial

Julie E. Ledgerwood et al.

JOURNAL OF INFECTIOUS DISEASES (2011)

Add to Collection

Review Immunology

DNA vaccines in veterinary use

Laurel Redding et al.

EXPERT REVIEW OF VACCINES (2009)

Add to Collection

Article Immunology

Long-term presence of memory B-cells specific for different vaccine components

A. M. Buisman et al.

VACCINE (2009)

Add to Collection

Article Immunology

Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+T cell immune responses compared to intramuscular injection and intradermal gene gun delivery

Simon R. Best et al.

VACCINE (2009)

Add to Collection

Review Immunology

Jump-starting the immune system: prime-boosting comes of age

DL Woodland

TRENDS IN IMMUNOLOGY (2004)

Add to Collection

Article Biotechnology & Applied Microbiology

Electroporation-facilitated delivery of plasmid DNA in skeletal muscle: Plasmid dependence of muscle damage and effect of poloxamer 188

J Hartikka et al.

MOLECULAR THERAPY (2001)

Add to Collection

© Peeref 2019-2024. All rights reserved.